---
title: "GenScript Biotech climbs 6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305895347.md"
description: "GenScript Biotech rose 6.21% to HK$31.46. Down 9.73% over five sessions and up 152.50% YTD."
datetime: "2026-11-18T01:31:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305895347.md)
  - [en](https://longbridge.com/en/news/305895347.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305895347.md)
generator: "portal-rs"
---

# GenScript Biotech climbs 6%

GenScript Biotech (1548.HK) climbed more than **6%** in Hong Kong trading to **HK$31.46**.

The stock is down 9.73% over the past five sessions and up 152.50% year to date. It sits 203.67% above its 52-week low of HK$10.36.

The Hang Seng Index is down 3.92% over the past five sessions and down 8.85% year to date.

The company has entered into a strategic partnership with Tencent Health on AI-driven drug discovery and development. The collaboration integrates Tencent's AI, high-performance computing and cloud capabilities with GenScript's life sciences experimental systems to advance a research model combining computational prediction with wet lab validation. GenScript will serve as a key wet lab validation partner for Tencent Health's BioNexus platform.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [01548.HK](https://longbridge.com/en/quote/01548.HK.md)

## Related News & Research

- [M Stanley: China AI Drug R&D Financing Accelerates, GENSCRIPT BIO  Benefits from Wet Lab Demand](https://longbridge.com/en/news/304828812.md)
- [Huatai Raises GENSCRIPT B-1K  Earnings Forecasts on AIDD Benefits, Reiterates Buy](https://longbridge.com/en/news/304381452.md)
- [Alibaba Q2 revenue rises on AI Cloud and Compute Services strength](https://longbridge.com/en/news/306100634.md)
- [Kuaishou Technology: Q3 loss and weaker revenue meet intensifying competition and costly AI investment](https://longbridge.com/en/news/306088382.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**